NextCure Inc NXTC:NASDAQ

Last Price$44.51NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/24/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$43.05 (1)
Ask (Size)$44.35 (1)
Day Low / HighN/A - N/A
Volume284.8 K
 

View Biotechnology IndustryPeer Comparison as of 01/24/2020

 

NextCure Inc ( NASDAQ )

Price: $44.51
Change: -2.59 (5.50%)
Volume: 284.8 K
4:00PM ET 1/24/2020
 
 

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $21.60
Change: -0.02 (0.09%)
Volume: 289.4 K
3:59PM ET 1/24/2020
 
 

Coherus BioSciences Inc ( NASDAQ )

Price: $18.14
Change: -0.01 (0.06%)
Volume: 1.3 M
3:59PM ET 1/24/2020
 
 

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $17.45
Change: -0.95 (5.16%)
Volume: 70.3 K
4:00PM ET 1/24/2020
 
 

Dicerna Pharmaceuticals Inc ( NASDAQ )

Price: $19.26
Change: 0.00 (0.00%)
Volume: 510.9 K
4:00PM ET 1/24/2020
 

Read more news Recent News

Analyst Actions: SunTrust Robinson Humphrey Initiates Coverage on NextCure at Buy, Price Target $78
9:30AM ET 1/13/2020 MT Newswires

NextCure (NXTC) has an average rating among analysts of buy, with an average price target of $66. Price: 56.70, Change: -1.67, Percent Change: -2.86 ...

Analyst Actions: Needham & Co Initiates Coverage on NextCure With Buy Rating, $72 Price Target
10:15AM ET 12/05/2019 MT Newswires

NextCure's (NXTC) average rating among analysts is a buy, with an average price target of $61. Price: 50.96, Change: -0.05, Percent Change: -0.10 ...

--Analyst Actions: BTIG Initiates Coverage on NextCure at Buy, Price Target $61
10:11AM ET 11/26/2019 MT Newswires

Price: 39.61, Change: -0.23, Percent Change: -0.57 ...

NextCure Prices Common Stock Offering at $36.75/Share
4:04AM ET 11/15/2019 MT Newswires

NextCure (NXTC) said Thursday that it priced its public offering of 4,077,192 common shares at $36.75 per share, for gross proceeds of about $150 million. ...

Company Profile

Business DescriptionNextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD. View company web site for more details
Address9000 Virginia Manor Road
Beltsville, Maryland 20705
Phone+1.240.399.4900
Number of Employees44
Recent SEC Filing01/13/20208-K
President, Chief Executive Officer & DirectorMichael S. Richman
Chief Operating OfficerTimothy Mayer
Chief Financial OfficerSteven P. Cobourn
Chief Scientific OfficerSolomon Langermann

Company Highlights

Price Open$47.15
Previous Close$47.10
52 Week Range$13.86 - 109.00
Market Capitalization$1.0 B
Shares Outstanding22.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/11/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.48
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-645.81%
Return on Equity-24.45%

Analyst Ratings as of 01/10/2020

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset